Late-onset Pneumocystis jirovecii pneumonia in solid organ transplant recipients

被引:29
作者
Perez-Ordono, L. [1 ]
Hoyo, I. [1 ]
Sanclemente, G. [1 ]
Ricart, M. J. [2 ]
Cofan, F. [2 ]
Perez-Villa, F. [3 ]
Puig de la Bellacasa, J. [4 ]
Moreno, A. [1 ]
Cervera, C. [1 ]
机构
[1] Univ Barcelona, Dept Infect Dis, Hosp Clin Barcelona, Barcelona, Spain
[2] Univ Barcelona, Hosp Clin Barcelona, Renal Transplant Unit, Barcelona, Spain
[3] Univ Barcelona, Hosp Clin Barcelona, Heart Transplant Unit, Barcelona, Spain
[4] Univ Barcelona, Hosp Clin Barcelona, Ctr Int Hlth Res CRESIB, CDB,Dept Microbiol, Barcelona, Spain
关键词
Pneumocystis jirovecii; PCP; late-onset opportunistic infection; solid organ transplantation; lymphopenia; rituximab; CARINII-PNEUMONIA; RITUXIMAB THERAPY; IMMUNOCOMPROMISED PATIENTS; CYTOMEGALOVIRUS-INFECTION; RISK-FACTORS; REJECTION; PROPHYLAXIS; PREVENTION; SIROLIMUS;
D O I
10.1111/tid.12184
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Anti-Pneumocystis prophylaxis is recommended for at least 6-12months after solid organ transplantation, as most cases of Pneumocystis jirovecii pneumonia (PCP) occur during the first year post transplantation. Herein, we report 4 cases of late-onset PCP (>1year post transplant). PCP appeared in a range of 50-68months post transplant. Two cases had history of humoral rejection episodes treated with rituximab, and the other 2 had low CD4+ T-cell count (<200 cells/mm(3)) at the time of diagnosis. All 4 patients survived. In conclusion, although the number of cases is low, we must be aware of the possibility of late-onset PCP in solid organ transplant patients. The role of previous use of rituximab or persistent CD4+ T-cell lymphopenia should be addressed in future studies.
引用
收藏
页码:324 / 328
页数:5
相关论文
共 29 条
[1]   Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients [J].
Arend, SM ;
Westendorp, RGJ ;
Kroon, FP ;
vantWout, JW ;
Vandenbroucke, JP ;
vanEs, LA ;
vanderWoude, FJ .
CLINICAL INFECTIOUS DISEASES, 1996, 22 (06) :920-925
[2]   Response:: Prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients -: As long as the pros outweigh the cons [J].
Arend, SM ;
van't Wout, JW .
CLINICAL INFECTIOUS DISEASES, 1999, 28 (02) :247-249
[3]   Prevention of infection due to Pneumocystis carinii [J].
Fishman, JA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (05) :995-1004
[4]   Prevention of infection caused by Pneumocystis carinii in transplant recipients [J].
Fishman, JA .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (08) :1397-1405
[5]  
Garcia-Gil D, 1996, Enferm Infecc Microbiol Clin, V14, P296
[6]   Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? [J].
Gordon, SM ;
LaRosa, SP ;
Kalmadi, S ;
Arroliga, AC ;
Avery, RK ;
Truesdell-LaRosa, L ;
Longworth, DL .
CLINICAL INFECTIOUS DISEASES, 1999, 28 (02) :240-246
[7]  
Hughes W T, 1998, Semin Respir Infect, V13, P283
[8]   Pneumocystis jiroveci Pneumonia Following Rituximab Treatment in Wegener's Granulomatosis [J].
Hugle, Boris ;
Solomon, Melinda ;
Harvey, Elizabeth ;
James, Adrian ;
Wadhwa, Anupma ;
Amin, Reshma ;
Bell-Peter, Audrey ;
Benseler, Susanne .
ARTHRITIS CARE & RESEARCH, 2010, 62 (11) :1661-1664
[9]   Pneumocystis jirovecii pneumonia 13 years post renal transplant following a recurrent cytomegalovirus infection [J].
Iqbal, A. H. Muhammad ;
Lim, S. K. ;
Ng, K. P. ;
Tan, L. P. ;
Chong, Y. B. ;
Keng, T. C. .
TRANSPLANT INFECTIOUS DISEASE, 2012, 14 (04) :E23-E26
[10]   Infectious Complications of Antilymphocyte Therapies in Solid Organ Transplantation [J].
Issa, Nicolas C. ;
Fishman, Jay A. .
CLINICAL INFECTIOUS DISEASES, 2009, 48 (06) :772-786